

9. 工程評価を行う上でのプリオン株の問題

現在工程評価にはvCJDのモデルとして、263K株などが主に使用されている。これは263K株が長期にわたりプリオン研究に用いられてきており、評価手法が確立していたことや、BSEやvCJDの動物馴化株がなかったことによる。しかしながら、263K株を評価に用いる場合は、BSE株、vCJD株の持つ蛋白分解酵素（PK）への抵抗性等の性状が異なる可能性があることを考慮する必要がある。また、再利用するデバイスや設備などのプリオン清浄化（不活化）に関しても、プリオン蛋白の持つ性状から慎重にその条件を設定する必要がある³⁵⁾。これらのことから、vCJDやBSEのモデルとして263K株を用いることによる影響を工程条件設定時や評価時には必ず意識しておくべきである。

米国赤十字のAkimovらは、vCJDのマウス馴化株及び細胞培養法を樹立した³⁶⁾。私たちはこの株と関連技術を導入し、vCJDを直接用いた評価試験技術確立とvCJDのモデルとしての263K株の妥当性に関する検討を進めている。vCJD感染マウス脳由来の超音波処理プリオン材料を用いて15nmろ過膜による異常型プリオン蛋白の除去特性をWB法で評価したところ、2.8Logの除去指数を示したものの、ろ液中に異常型プリオン蛋白を認められた（Table 3）³⁷⁾。この結果から、同じ方法で調製したプリオン材料を用いたろ過実験では、263K株も、vCJD株も同様のろ過（除去）特性を示すことが明らかになった。しかしながら263K株はこれまでWBレベルで15nmろ過後液には検出された事がなかったのに対して、vCJD株は検出された。この結果は検出感度によるものなのか、263K株とvCJD株由来の異常型プリオンの物性の違いによるものなのか、現時点で判断することはできない。感染性を含めた詳細を更に検討する必要がある。

Table 3. 15nmろ過膜によるvCJD及び263K由来・超音波処理マイクロソーム画分中の異常型プリオン蛋白の除去。

	vCJD	263K
ろ過前	3.1	4.2
ろ過後	0.3	<1.0
除去指数	2.8	≥3.2

ウエスタンブロットリング（WB法）による検出。数値はNon-detectable endpoint法によって求めた総Log₁₀値で示した。

10. リスク評価を行う上での留意点

工程評価を行う上でのプリオン材料の留意点は上述の通りであるが、製剤のリスク評価を行うにあたっては他にも留意すべき点がある。まず、製剤のリスク評価はいくつかの施策の組合せによって完成するという点が挙げられる。人工酸素運搬体のリスク評価を行う場合、原料に対する評価と工程に対する評価が基本となる。そしてその製剤を投与される患者に対するリスク・ベネフィットに基づき有用性の判断を行うことになる。

原料に対する評価は、1ロットの製剤を製造するための原料

（赤血球）に異常型プリオン蛋白が混入する量を疫学的に推定することによって行う。現在、日本では輸血によるvCJDの発生確率は1人と考えられている³⁸⁾。現在、ヒト血液中のvCJDの感染価を定量的に推測することができないが、英国ではvCJDに汚染していると思われる輸血例66例中4例が感染している³⁸⁾。vCJD感染マウスのBuffy coat、赤血球及び血漿を静注ルートによりマウスに感染させたところ、Buffy coatと血漿は感染性を示し、赤血球画分は感染性を示さなかった³⁴⁾。これらの知見に基づけば、日本の献血由来のvCJD陽性原料を製造に用いる可能性はほとんどないと解釈されるが、原料画分には感染性が認められることから、任意のロットに混入する推定最大量は1単位（ドナー）となる。よって、工程の評価はこれを基準として考えることになる。

具体的な対策として、次の対策が考えられる。まず、採血時に白血球除去膜処理を導入し、原料段階でのリスク低減策を講じる。白血球除去膜は白血球除去によるリスク低減に加え、プリオン蛋白そのものの除去が期待できる。しかしながら白血球除去膜によるプリオン蛋白除去については一部の製品を除き評価は定まっていない^{11,12,25)}。次に製造工程におけるリスク低減を行う。工程にはプリオン除去の堅牢性を確保するために、除去能力を示す複数の工程を導入する。この能力についてはガイドラインに従って評価する必要がある。ウイルスを対象とした評価においては数値目標が設定されているが、プリオンを対象とした評価では現時点で数値目標は設定されていない^{39,40,41)}。このことから、プリオンを対象とした評価において、目標とする数値の妥当性や必要とする安全係数についての更なる議論が必要であり、得られた数値（RLF）だけで安全性を判断するのは時期尚早である。むしろ、製造工程中にプリオン除去の機軸が異なる工程を複数導入することによってセーフティーネットを構成する方が効果的であり、工程の堅牢性も高くなると考えられる。

血漿分画製剤やHb精製工程に導入可能と思われるデバイスは、採血時の白血球除去フィルターの他に、ウイルス除去フィルター、デプスフィルター、荷電された除菌・清澄ろ過フィルター等があり、蛋白質の精製工程としては、エタノール分画、硫酸分画、ポリエチレングリコール分画、クロマトグラフィー等が考えられ、複数の工程対応は可能と考えられる。なお、目標とする除去係数やその妥当性を評価するために血液中の感染性プリオンの性状や感染価についての更なる研究が望まれる。

工程での除去能力はプリオンに対する安全性確保の根幹となるので慎重な試験デザインと解釈が求められる。基本的な手法はガイドライン^{11,39,40,42)}に記述されているが、ガイドラインは策定時のMinimum requirementであって、指針のひとつにすぎない。よって、実際にはその製剤と製造工程の特性を良く理解した上でデザインしなければならない。工程のプリオン除去評価を行うにあたって、WBレベルで検出限界以下になったプリオン除去に関する重要工程については、動物への接種実験で感染性の有無を確認することが望ましい⁴³⁾。また、プリオン蛋白の実態が良く分かっていない以上、不十分な知識や誤解に基

づくデザインによる評価試験の結果解釈は誤った判断を導く可能性を秘めていることを明確に理解しておかなければならない。製剤の有効性と安全性は承認審査の時に評価されるが、有用性は科学技術の進歩により得られたプリオンに関する新しい知見に基づき、その時々により評価・確保されなければならないことも理解しておくべきである。

謝辞

本研究の一部は大阪大学微生物病研究所、酪農学園大学獣医学部、米国赤十字、ベネシスの共同研究として実施された。また、本研究の一部は厚生労働科学研究（H22 - 医薬 - 一般 - 006）として実施された。本稿を執筆するにあたって、榑ベネシス岡島文子氏、池田美朗氏の貢献に深謝します。これらの共同研究の成果が血液製剤領域のみならずバイオ医薬品領域の安全性向上に役立つことを願います。


引用文献

1. World Organization for Animal Health. Number of reported cases of bovine spongiform encephalopathy (BSE) in farmed cattle worldwide. http://www.oie.int/eng/info/en_esbmonde.htm (2010.12.22 downloaded)
2. 食品安全委員会。「牛海綿状脳症（BSE）と変異型クロイツフェルト・ヤコブ病（vCJD）」について。 http://www.fsc.go.jp/sonota/faq_bse-tori.html (2010.12.22 downloaded)
3. 農林水産省。BSE 患畜発生状況。 http://www.maff.go.jp/j/syuan/douei/bse/b_kantiku/index.html (2010.12.22 downloaded)
4. The European Creutzfeldt Jakob Disease Surveillance Network. vCJD cases Worldwide. <http://www.eurocjd.ed.ac.uk/> (2010.12.22 downloaded)
5. Eurosurveillance editorial team. First case of vCJD reported in a Japanese patient. *Eurosurveillance*. 10 February 2005; 10(6). <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=2640> (2011.1.9 downloaded)
6. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. *Science*. 1982; 216: 136-44.
7. Robakis NK, Devine-Gage EA, Jenkins EC, Kascsak RJ, Brown WT, Krawczun MS, Silverman WP. Localization of a human gene homologous to the PrP gene on the p ARM of chromosome 20 and detection of PrP-related antigens in normal human brain. *Biochem Biophys Res Commun* 1986; 140: 758-765.
8. Silveira JR, Raymond GR, Hughson AG, Race RE, Sim VL, Hayes SF, Caughey B. The most infectious prion protein particles. *Nature* 2005; 437: 257-261.
9. 厚生省薬務局審査課・薬務局医療機器開発課。ウシ由来物を用いた医薬品等に関する調査依頼について。薬審第165号平成8年3月27日。
10. 厚生省医薬安全課長。ウシ等由来物を原料として製造される医薬品等の品質及び安全性確保について。医薬発第1226号平成12年12月12日。
11. Committee for Medicinal Products for Human Use (CHMP), European Medical Agency. CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. Draft EMEA/CPMP/BWP/2879/02/rev 2. 24 June 2010.
12. European Medical Agency. Concept Paper on the Need To Update the CHMP Position Statement on CJD and Plasma-Derived and Urine-Derived Medicinal Products. EMEA/CHMP/BWP/253246/2009. 23 July 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003742.pdf (2011.1.8 downloaded)
13. Committee for Medicinal Products for Human Use (CHMP) and Committee for Advanced Therapies (CAT), European Medicines Agency. CHMP/CAT position statement on Creutzfeldt-Jakob disease and advanced therapy medicinal products. Draft, EMEA/CHMP/CAT/BWP/353632/2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/07/WC500095069.pdf (2010.12.24 downloaded)
14. 厚生労働省医薬局長。ウシ等由来物及び人由来物を原料として製造される医薬品、医療器具等の品質及び安全性確保の強化について。医薬発第0414005号平成15年4月14日
15. National Blood Service Scottish National Blood Transfusion Service Welsh Blood Service and Northern Ireland Blood Transfusion Service National CJD Surveillance Unit. TRANSFUSION MEDICINE EPIDEMIOLOGY REVIEW (TMER). <http://www.cjd.ed.ac.uk/TMER/TMER.htm> (2010.12.25 downloaded)
16. World Health Organization. Tables on Tissue Infectivity Distribution in Transmissible Spongiform Encephalopathies Updated 2010. WHO/EMP/QSM/2010.I. <http://www.who.int/bloodproducts/tablestissueinfectivity.pdf> (2010.12.25 downloaded)
17. Peden A, McCardle L, Head MW, Love S, Ward HJ, Cousens SN, Keeling DM, Millar CM, Hill FG, Ironside JW. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. *Haemophilia* 2010; 16: 296-304.
18. vCJD abnormal prion protein found in a patient with haemophilia at post mortem. Health Protection Agency. Press release, 17 February 2009. <http://www.hpa.org.uk/NewsCentre/NationalPressReleases/2009PressReleases/090217vCJDABNORMALPRIONPROTEINFOUNDINAPATIENTWITH/> (2010.12.24 downloaded)
19. 21st Meeting of the Transmissible spongiform Encephalopathies Advisory Committee. June 12, 2009.

- <http://www.fda.gov/downloads/AdvisoryCommittees/Calendar/UCM164322.pdf>
20. A 2010 Update of the Draft Quantitative Risk Assessment of vCJD Risk Potentially Associated with the Use of Human Plasma-Derived Factor VIII Manufactured Under United States (US) License From Plasma Collected in the US. October 6, 2010. Center for Biologics Evaluation and Research US Food and Drug Administration. <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/TransmissibleSpongiformEncephalopathiesAdvisoryCommittee/UCM231018.pdf> (2010.12.24 downloaded)
 21. ヒト・プリオン病－感染症としての変遷と新たな課題. 萩原健一, 山河 芳夫, 花田 賢太郎. ウイルス. 2009; 59: 155-166
 22. 薬事・食品衛生審議会 平成21年度 第3回 血液事業部会運営委員会資料「変異型Creutzfeldt-Jakob病 (vCJD) の国内外の発生状況」. 山田正仁. <http://www.mhlw.go.jp/shingi/2009/12/dl/s1210-8n.pdf> (2010.12.25 downloaded)
 23. 薬事・食品衛生審議会 平成21年度 第3回 血液事業部会運営委員会資料「英国渡航に由来するvCJD感染リスクの評価と献血制限のあり方について」. 梯 正之. <http://www.mhlw.go.jp/shingi/2009/12/dl/s1210-8o.pdf> (downloaded 2010.12.25)
 24. Tattum MH, Jones S, Pal S, Khalili-Shirazi A, Collinge J, Jackson GS. A highly sensitive immunoassay for the detection of prion-infected material in whole human blood without the use of proteinase K. *Transfusion*. 2010; 50: 2619-2627.
 25. FDA. Informational Issue Summary, FDA's Currently-Recommended Policies to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products Transmissible Spongiform Encephalopathies Advisory Committee 22nd Meeting October 28-29, 2010. <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/TransmissibleSpongiformEncephalopathiesAdvisoryCommittee/UCM2311179.pdf> (2010.12.25 downloaded)
 26. 日本赤十字社ホームページ. <http://www.jrc.or.jp/donation/refrain/detail/detail09.html> (2010.12.25 downloaded)
 27. Yunoki M, Urayama T, Ikuta K. Possible removal of prion agents from blood products during the manufacturing process. *Future Virol* 2006; 1: 659-674.
 28. 人工赤血球. *New Current*. 2006.9.1; 17: 2-10.
 29. 武岡真司. 分子集合科学を利用した人工血液の創世. *人工血液* 2005; 13: 136-147.
 30. Yunoki M, Tanaka H, Urayama T, Hattori S, Ohtani M, Narita Y, Kawabata Y, Miyatake Y, Nanjo A, Iwao E, Morita M, Wilson E, MacLean C and Ikuta K. Prion removal by nanofiltration under different experimental conditions. *Biologicals* 2008; 36: 27-36.
 31. Yunoki M, Tanaka H, Urayama T, Kanai Y, Nishida A, Yoshikawa M, Ohkubo Y, Kawabata Y, Hagiwara K, Ikuta K. Infectious prion protein in the filtrate even after 15nm filtration. *Biologicals*. 2010; 38: 311-313.
 32. Berardi VA, Cardone F, Valanzano A, Lu M, Pocchiari M. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation. *Transfusion*. 2006; 46: 652-8.
 33. 柚木幹弘, 浦山健, 西田真直, 辻川宗男, 堀井肇, 西横秀雄, 上村八尋, 鎌谷昌男, 佐藤進一郎, 加藤俊明, 関口定美. Antithrombin-III製剤の製造工程のウイルスバリデーション試験. *医薬品研究*. 1999; 30: 331-341.
 34. Cervenakova L, Yakovleva O, McKenzie C, et al: Similar levels of infectivity in the blood of mice infected with humanderived vCJD and GSS strains of transmissible spongiform encephalopathy. *Transfusion* 2003; 43: 1687-1694.
 35. Lee D*, Lebing W, Stenland C, Petteway S. Methods of inactivation of transmissible spongiform encephalopathies (TSEs) as applied to production chromatography processes. *DownStream* 27: 18-22. [http://www.gelifesciences.com/aptrix/upp00919.nsf/Content/B1A81AC9A032FB48C1257628001CD8A9/\\$file/18113084.pdf](http://www.gelifesciences.com/aptrix/upp00919.nsf/Content/B1A81AC9A032FB48C1257628001CD8A9/$file/18113084.pdf) (2011.1.9 downloaded)
 36. Akimov S, Yakovleva O, Vasilyeva I, McKenzie C, Cervenakova L. Persistent propagation of variant Creutzfeldt-Jakob disease agent in murine spleen stromal cell culture with features of mesenchymal stem cells. *J Virol*. 2008; 82: 10959-19562. Epub 2008 Aug 20.
 37. 久保 純, 大久保祐士, 中川 典子, 佐々木祐子, 柚木 幹弘, Larisa Cervenakova, 萩原 克郎, 生田 和良. vCJDを用いた血漿分画製剤の工程評価. 第58回日本ウイルス学会学術集会 (2010徳島)
 38. Shimian Z, Chyang TF, Lawrence B, Schonberger. *Transfusion transmission of human prion diseases. Transfusion Med Rev* 2008; 20: 58-69
 39. The European agency for the evaluation of medicinal products/committee for proprietary medical products (CPMP) biotechnology working party: Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP/BWP /268/95. 14 Feb. 1996.
 40. 厚生省医薬安全局長. 血漿分画製剤のウイルスに対する安全性確保に関するガイドラインについて. *医薬発*第1047号 1999.8.30

41. 厚生労働省医薬食品局長. 「血液製剤等に係る遡及調査ガイドライン」の一部改正について. 薬食発第1226008号, 薬食発第1226009号, 薬食発第1226010号, 薬食発第1226011号. 平成20年12月26日

42. 厚生省医薬安全局審査管理課長. 「ヒト又は動物細胞株を用いて製造されるバイオテクノロジー応用医薬品のウイルス安全性評価」について. 医薬審第329号 平成12年2月22日



Analysis of oligomeric stability of insulin analogs using hydrogen/deuterium exchange mass spectrometry

Shiori Nakazawa^{a,b}, Noritaka Hashii^{a,*}, Akira Harazono^a, Nana Kawasaki^{a,b}

^aDivision of Biological Chemistry and Biologicals, National Institute of Health Sciences, 1–18–1 Kami-yoga, Setagaya-ku, Tokyo 158-8501, Japan

^bGraduate School of Life Science, Hokkaido University, Kita 12–Nishi 6, Kita-ku, Sapporo 060-0812, Japan

ARTICLE INFO

Article history:

Received 8 July 2011

Received in revised form 9 August 2011

Accepted 1 September 2011

Available online 7 September 2011

Keywords:

Insulin

HDX/MS

Oligomeric stability

ABSTRACT

Insulin analog products for subcutaneous injection are prepared as solutions in which insulin analog molecules exist in several oligomeric states. Oligomeric stability can affect their onset and duration of action and has been exploited in designing them. To investigate the oligomeric stability of insulin analog products having different pharmacokinetics, we performed hydrogen/deuterium exchange mass spectrometry (HDX/MS), which is a rapid method to analyze dynamic aspects of protein structures. Two rapid-acting analogs (lispro and glulisine) incorporated deuteriums more and faster than recombinant human insulin, whereas a long-acting analog (glargine) and two intermediate-acting preparations (protamine-containing formulations) incorporated them less and more slowly. Kinetic analysis revealed that the number of slowly exchanged hydrogens (D_s) ($k < 0.01 \text{ min}^{-1}$) accounted for the difference in HDX reactivity among analogs. Furthermore, we found correlations between HDX kinetics and pharmacokinetics reported previously. Their maximum serum concentration (C_{max}) was linearly correlated with D_s ($r = 0.88$) and the number of maximum exchangeable hydrogens (D_{∞}) ($r = 0.89$). The maximum drug concentration time (t_{max}) was also correlated with reciprocals of D_s and D_{∞} ($r = 0.86$ and $r = 0.96$, respectively). Here we demonstrate the ability of HDX/MS to evaluate oligomeric stability of insulin analog products.

© 2011 Elsevier Inc. All rights reserved.

Insulin is a peptide hormone consisting of two peptides: an A chain with 21 amino acids and a B chain with 30 amino acids. Insulin is the only hormone in vertebrates to induce cellular uptake of glucose and lower blood glucose levels, and it is an essential drug for treating diabetes mellitus.

As a drug product, insulin molecules primarily form hexamers, which diffuse and dilute in the subcutaneous tissue after injection [1] and dissociate into monomers via dimers or tetramers [1,2]. Monomeric insulin is absorbed into microvessels to exert its pharmacological action [3]. Therefore, oligomeric stability is a crucial property of insulin, determining its onset and duration of action (Fig. 1).

To mimic the intrinsic insulin secretion and enable better control of blood glucose levels, several recombinant human insulin analogs with different onset and duration of action have been developed and marketed. Compared with the basic preparation of recombinant human insulin, insulin analog products are generally categorized on the basis of differences in the onset and duration of their action—rapid-acting, long-acting, and intermediate-acting groups. Fig. 2 and Table 1 present the primary structures and several characteristics of insulin analogs investigated in this study

[4–6]. Insulin lispro (lispro) is a rapid-acting insulin analog in which the positions of proline at B28 and lysine at B29 are reversed. Insulin glulisine (glulisine) is another major rapid-acting analog in which asparagine and lysine at positions B3 and B29 are replaced by lysine and glutamic acid, respectively. The amino acid substitutions in lispro and glulisine lead to a decrease in oligomeric stability; therefore, they act rapidly after subcutaneous injection. Insulin glargine (glargine) is a long-acting analog in which asparagine at position 21 on the A chain is substituted by glycine and two arginine residues are added to the C terminus of the B chain. Glargine has a higher isoelectric point (6.7) [7,8] than human insulin and its analogs, which range from 5.0 to 5.5 [9–12]. Glargine formulated at pH 3.5 to 4.5 precipitates in neutral conditions after subcutaneous injection [13,14]. Its precipitant gradually dissociates and is absorbed slowly into the bloodstream, and thereby glargine has a slower onset and longer duration of action than human insulin. Insulin detemir (detemir) is another type of long-acting analog that was designed with a concept different from modification of oligomeric stability. Detemir, in which a myristic acid is covalently bound to lysine at B29, binds to albumin in subcutaneous tissues and plasma. This modification leads to delay in absorption and prolongation of the serum half-life. The intermediate-acting group is another type of insulin with longer action in which the hexameric insulin (analog) is stabilized by forming a

* Corresponding author. Fax: +81 3 3700 9084.

E-mail address: hashii@nihs.go.jp (N. Hashii).




Fig. 1. Absorption of subcutaneously injected insulin. Insulin molecules in drug products exist mainly as hexamers. After subcutaneous injection, diluted hexamers dissociate to monomers to be absorbed by microvessels.




Fig. 2. Primary structures of insulin analogs we examined. Dashed lines represent disulfide bonds. Mutated residues are underscored.

Table 1
Human insulin and its analog products examined in this study.

Group	Analog	Onset of action	Duration of action	Molecular weight	pI	pH of drug product
Rapid	Human Insulin	30–60 min	4–12 h	5807.57	5.4	7.0–7.8
	Lispro	5–15 min	4–6 h	5807.57	5.65	7.0–7.8
Long	Glulisine	5–15 min	1–2.5 h	5822.58	5.1	7.0–7.8
	Glargine	2–4 h	20–24 h	6062.89	6.7	3.5–4.5
	Detemir	2 h ^a	6–24 h ^a	5916.82	7.2	7.2–7.6
Intermediate	NPH	2–4 h	10–16 h	5807.57	7.0	7.0–7.5
	NPL	1–2 h	10–16 h	5807.57	7.0	7.0–7.8

^a Dose dependent.

complex with protamine to suppress dissociation in subcutaneous tissue after injection. Human isophane insulin (neutral protamine




Fig. 3. Schematic model of HDX/MS. The protein sample is exposed to deuterated solvent and subjected to MS. Hydrogen atoms, without participating in hydrogen bonds or any other noncovalent bonds, are more easily exchanged with deuteriums. Exchanged deuteriums are detected as the shift in *m/z* value distributions.

Hagedorn, NPH)¹ and a lispro preparation containing protamine (neutral protamine lispro, NPL) belong to the intermediate-acting group.

Evaluation of oligomeric states of formulated insulin analogs is important to support their appropriate use. Previously, the oligomeric states of insulin analogs were determined by sedimentation velocity or static light scattering or were estimated by comparing their circular dichroism spectra under different conditions [15]. However, the oligomeric stability of these formulated insulin analogs have not been investigated because of the absence of convenient methods. Therefore, there is an increasing need for an easy, rapid, and accurate method to evaluate stability of the association state of insulin.

Hydrogen/deuterium exchange mass spectrometry (HDX/MS) is a known method to analyze structural fluctuations of proteins [16–18]. HDX/MS is based on the exchange reaction between hydrogens in proteins and deuteriums in the D₂O solvent. A protein sample is incubated in a D₂O solvent to incorporate deuteriums, and then the sample solution is mixed with an acidic reagent to suppress the HDX reaction. The number of incorporated deuteriums is calculated from the difference in the average mass obtained by liquid chromatography mass spectrometry (LC/MS) before and after the HDX reaction (Fig. 3). Deuteriums that were exchanged with amide hydrogens in the protein backbone are primarily detected by HDX/MS because hydrogens in protein side chain groups (e.g., –OH, –NH₂, –SH, –COOH, –CONH₂) have lower pK_a values, have higher exchange rates even after the addition of H⁺, and undergo a back-exchange reaction to lose deuteriums [19]. The exchange rate of each amide hydrogen depends on its interaction with the solvent [20–22]. A moiety with more structural fluctuations, which is not involved in an α-helix or a β-sheet, not packed in the hydrophobic core, and not trapped in other interactions, has more solvent accessibility. Thus, a moiety or molecule that interacts with the solvent further (e.g., a monomer vs. an oligomer) will gain more exchanged deuteriums [23].

¹ Abbreviations used: NPH, neutral protamine Hagedorn; NPL, neutral protamine lispro; HDX/MS, hydrogen/deuterium exchange mass spectrometry; LC/MS, liquid chromatography mass spectrometry; HPLC, high-performance liquid chromatography; PCA, principal component analysis; DSL, dynamic light scattering.

HDX/MS can potentially be applied to estimate the stability of insulin oligomers.

In this study, we compared the HDX reactivity of insulin analog formulations with different oligomeric stability and different drug dispositions. We found correlations between their HDX kinetic parameters and their pharmacokinetic parameters. Here we demonstrate the usefulness of HDX/MS to evaluate oligomeric stability of insulin analog products and propose its potential use for predicting their onset and duration of action.

Materials and methods

Materials

Human insulin (Humulin R), insulin lispro (Humalog), NPH insulin (Humulin N), and NPL (Humalog N) were purchased from Eli Lilly (Indianapolis, IN, USA). Insulin glargine (Lantus) and insulin glulisine (Apidra) were purchased from Sanofi-Aventis (Paris, France). Insulin detemir (Levemir Penfill) was purchased from Novo Nordisk (Bagsværd, Denmark). All compounds were provided at a concentration of 100 U/ml, approximately 3.5 mg/ml (0.61 mM). Ammonium acetate and formic acid were purchased from Wako Pure Chemical Industries (Osaka, Japan). Acetonitrile and D₂O were purchased from Sigma-Aldrich (St. Louis, MO, USA).

HDX/MS

Protein solutions were diluted 10-fold with 10 mM ammonium acetate in 90% D₂O (pH 7.4) and kept on ice during the HDX reaction because conducting the reaction at room temperature resulted in a very high exchange rate that made it difficult to successfully observe a time-dependent change. Final concentrations of insulin analogs were approximately 60 mM (0.35 mg/ml). At each time point, 50 µl of the reaction solution was mixed with an equal volume of ice-chilled formic acid/acetonitrile/water (1:49:50) to repress the exchange reaction; this step is called "quenching." Deuterated proteins were introduced into the mass spectrometer with the Paradigm MS4 HPLC (high-performance liquid chromatography) system (Michrom BioResources, Auburn, CA, USA) through

Table 2
Hydrodynamic diameters of insulin analogs in 10 mM ammonium acetate (pH 7.4).

	Concentration (µM)			
	15	30	60	120
Insulin	4.7 ± 0.1	5.1 ± 0.3	4.7 ± 0.1	4.6 ± 0.1
Lispro	3.2 ± 0.4	3.6 ± 0.6	4.4 ± 0.2	4.6 ± 0.1
Glulisine	3.3 ± 0.6	3.7 ± 0.2	4.5 ± 0.1	4.5 ± 0.3
Glargine	609.1 ± 42.8	284.2 ± 8.2	274.0 ± 28.0	4.9 ± 0.1
Detemir	13.2 ± 0.1	11.0 ± 2.9	6.2 ± 0.0	5.4 ± 0.1
Insulin/H ⁺			2.6 ± 1.0	

Note. Values are mean diameters (nm) ± standard deviations (n = 3).

Table 3
Relative volume in neutral buffer compared with that of human insulin in acidic solution.

	Concentration (µM)			
	15	30	60	120
Insulin	5.9	7.6	6.2	5.8
Lispro	1.9	2.8	5.1	5.5
Glulisine	2.1	2.9	5.4	5.3
Glargine	1.3 × 10 ⁷	1.3 × 10 ⁶	1.2 × 10 ⁶	6.8
Detemir	131.6	77.2	14.0	9.2

Note. Relative volume (to insulin/H⁺) was calculated as (mean diameter of each analog at each concentration)³/(mean diameter of insulin/H⁺)³.

Table 4
HDX kinetics of insulin analogs.

	Number of exchangeable hydrogens				
	Maximum (D _∞)	(D ₀)	Slow (D _s)	Medium (D _i)	Fast (D _f)
Insulin	20.3	(11.9)	3.9	1.5	3.0
Lispro	24.5	(12.2)	7.3	2.6	2.5
Glulisine	24.7	(12.1)	7.2	2.6	2.8
Glargine	18.0	(10.1)	2.0	1.8	4.2
Detemir	19.9	(12.7)	3.3	1.6	2.5
NPH	16.4	(9.9)	1.0	1.8	3.6
NPL	16.9	(11.8)	1.3	2.0	1.8

Note. Shown are numbers of maximum exchangeable hydrogens and slow-exchanging ($k \leq 0.1 \text{ min}^{-1}$), intermediate-exchanging ($0.1 < k \leq 1$), or fast-exchanging ($k > 1.0$) hydrogens that were calculated on the basis of Eq. (1). D_t values of when $t = 0$ are in parentheses.

an L-column Micro trap column with C18 solid phase (Chemicals Evaluation and Research Institute, Tokyo, Japan) at a flow rate of 50 µl/min over 10 min with 0.1% formic acid in 50% acetonitrile. Mass spectra were recorded using a Fourier transform ion cyclotron resonance mass spectrometer (LTQ-FT, Thermo Fisher Scientific, Waltham, MA, USA) equipped with a nano-electrospray ion source (AMR, Tokyo, Japan). The conditions for MS analysis were as follows: an electrospray voltage of 2.5 kV in positive ion mode, a capillary temperature of 200 °C, and an m/z range of 1000 to 4000. The number of incorporated deuteriums was determined by subtraction of the weight-average molecular weights.

Calculation of kinetic parameters

The modeling and calculation of deuterium incorporation were done using Mathcad 14.0 software (PTC, Needham, MA, USA). Details of fitting with Eq. (1) are described in Results.

Size distribution measurements

Hydrodynamic diameter distributions were determined with the dynamic light scattering method by Zetasizer Nano (Malvern Instruments, Worcestershire, UK). Insulin analog products were diluted with 10 mM ammonium acetate (pH 7.4) to 15, 30, 60, and 120 µM. Acidic solution of insulin for the control was prepared with Humulin R and a 9-fold volume of 0.1% formic acid, which had a final pH of 2.7 at 25.7 °C. Overnight equilibration was performed at 4 °C prior to measurements. The relative volume given in Table 3 was calculated as the cube of the ratio of the mean diameter to that of insulin/H⁺.

Multivariate analysis

Principal component analysis (PCA) was performed using SIM-CA-P⁺ software (Umetrics, Umeå, Sweden) with the PCA method. As the variables, the numbers of maximum exchangeable hydrogens (D_∞), and slow- and intermediate-exchanging hydrogens (D_s and D_i, respectively) (Table 4) were input. Before input, the variables were divided by the number of amide hydrogens in the main chains of each analog.

Results

Hydrodynamic diameter distributions of insulin analog products

To confirm the oligomeric states of insulin analogs used in this study, the particle size of four analogs (lispro, glulisine, glargine, and detemir) were measured by dynamic light scattering (DLS) after dilution of these analogs with an H₂O solvent of the same

composition as HDX solvent (Tables 2 and 3). As a control, an acidic solution of 60 μM human insulin (insulin/ H^+), in which insulin exists mainly as a mixture of monomers and dimers, was prepared [24]. At a high concentration (120 μM), the mean diameters of the four analogs obtained by DLS were similar to that of human insulin. In addition, their volumes calculated from the mean diameters were 6-fold larger than that of insulin/ H^+ (Table 3), suggesting that they could exist as hexamers at a high concentration.

At lower concentrations (15 and 30 μM), the mean diameters of the two rapid-acting analogs, lispro and glulisine, were smaller than the diameters at higher concentrations, although the diameter of human insulin remained roughly constant at all concentrations. These data indicate that the rapid-acting analogs dissociate more rapidly than human insulin. Glargine, with an isoelectric point of 6.7, showed an increase in diameter with a decrease in concentration by dilution with a neutral solvent, indicating the aggregation of glargine molecules. At lower concentrations (15 μM), detemir formed large particles approximately 130 times larger than insulin/ H^+ , possibly suggesting the association of detemir molecules at lower concentrations. These results are consistent with the prevailing oligomeric stability of insulin analogs except for detemir.

HDX/MS of human insulin and insulin analogs

First, to determine deuterium incorporation by human insulin as the standard, human insulin was subjected to the HDX reaction and LC/MS as described in Materials and Methods. To conduct exchange reaction under physiological pH conditions, we selected




Fig. 4. Representative mass spectra of human insulin observed during the HDX procedure. The original spectrum of human insulin without deuterium label [D(-)] and spectra obtained at several time points of HDX reaction are shown.




Fig. 5. Time-series plot of deuterium uptake by insulin analog products.

ammonium acetate buffer, one of the better buffers to mimic *in vivo* pH condition, considering applicability to the mass spectrometer. The time-dependent shift of the mass spectra and the number of incorporated deuteriums by human insulin are shown in Figs. 4 and 5 (red rhombus). The uptake was fast during the first 5 min, and approximately 80% of the incorporation was complete within the first minute. After 3 h of the HDX reaction, the number of incorporated deuteriums was 19.82 ± 1.64 (mean \pm standard deviation, $n = 4$).

Next, to determine whether the HDX reactivity of rapid-, long-, or intermediate-acting insulin analogs differed from that of human insulin, six analog products were examined (Fig. 5). Lispro and glulisine exhibited higher exchange reactivity than human insulin (24.48 ± 1.10 and 24.74 ± 0.70 , respectively, after a 3 h reaction, $n = 3$), but glargine showed lower exchange reactivity than human insulin (17.57 ± 0.42 after 3 h, $n = 3$), indicating its enhanced oligomeric stability. Similarly, two formulations of the intermediate-acting group, NPH and NPL, also had lower reactivity (16.32 ± 0.43 and 16.39 ± 1.03 , respectively, after 3 h, $n = 3$). Unlike the other analogs, detemir had a similar number of incorporated deuteriums as human insulin (19.84 ± 0.40 after 3 h, $n = 3$).

Kinetics of HDX reactivity of insulin analogs

To obtain further information on the oligomeric stability of insulin analogs, we investigated the kinetics of HDX reactions of human insulin and the insulin analogs. In general, HDX reactions of proteins can be modeled as a pseudo-first-order reaction [21], and exchangeable amide hydrogens are classified into three kinetic groups: fast-, intermediate-, and slow-exchanging hydrogens [25]. On these bases, we calculated the kinetics using Eq. (1), a tetranomial function of reaction time (t) defined by reaction rate constants of each hydrogen group (k_f , k_i , and k_s), denoting the maximum number of exchangeable hydrogen atoms by D_∞ , and the number of hydrogens of each kinetic group by D_f , D_i , and D_s . The latter three terms represent the hydrogens that have not been exchanged after a t -min reaction. We employed the tetranomial model because it gave higher values of Pearson correlation coefficients than modeling with three or five terms:

$$D_t = D_\infty - D_f \exp(-k_f t) - D_i \exp(-k_i t) - D_s \exp(-k_s t). \quad (1)$$

The sets of coefficients (D_f , D_i , D_s , and D_∞) and reaction rate constants (k_f , k_i , and k_s) that gave the highest Pearson correlation coefficients were sought by fitting the mean number of incorporated




Fig. 6. The score plot for the PCA of the HDX kinetic parameters. Primary (PC1) and secondary (PC2) principal components are indicated.

deuteriums at every observed time point to Eq. (1). The resulting values for D_f , D_i , D_s , and D_∞ are shown in Table 4. The fast-acting group had the highest D_∞ , followed by the human insulin, long-acting, and intermediate-acting groups. Interestingly, the number of hydrogens that were already exchanged at the beginning of the HDX reaction (D_t when $t=0$) was not different among the respective groups, suggesting that differences in D_∞ originated from hydrogens that had lower exchange reaction rates and, therefore, were not exchanged during the first few seconds. Furthermore, D_s of the rapid-acting analogs were increased compared with those of the other groups. From these results, the number of D_s could be related to the difference in the overall HDX reactivity among insulin analogs.

PCA using HDX kinetic parameters of insulin analogs

We examined whether rapid-, long-, and intermediate-acting groups were distinguished by PCA using the HDX kinetic parameters, D_∞ , D_f , D_i , and D_s . The score plots for PC1 and PC2 are shown in Fig. 6. Lispro and glulisine were plotted at neighboring positions, distant from human insulin and other analogs. In addition, three preparations with a lower tendency for dissociation (i.e., glargine, NPH, and NPL) were plotted closely together. However, detemir was plotted near human insulin, not near analogs of the long-acting group. This result demonstrates that the insulin analogs with different pharmaceutical properties are distinguished by their HDX reactivity.

Pharmacokinetic parameters and HDX kinetics of insulin analogs

We analyzed the association between the HDX kinetic parameters and the actual pharmacokinetic parameters in humans. We compared previously reported values [11,26–32] of the maximum plasma concentrations (C_{max}) and the maximum drug concentration time (t_{max}) after subcutaneous injection with our kinetic parameters, D_∞ , D_s , D_i , and D_f (Table 5). Detemir, employing the affinity to albumin instead of the oligomeric stability for its longer action, was excluded. C_{max} had linear correlations with D_∞ and D_s ($r=0.88$ and $r=0.89$, respectively) (Fig. 7A). In addition, t_{max} correlated with reciprocals of D_∞ and D_s ($r=0.86$ and $r=0.96$, respectively) (Fig. 7B).

Table 5
Reported values of C_{max} and t_{max} .

Analog	C_{max} ($\mu\text{U/ml}$)	t_{max} (min)	Reference
Insulin	43.3	109	[26]
	35.8	97.5	[27]
	40.0	104	[28]
	46.0	92	[28]
	46.0	82	[29]
Lispro	51.1	101	[11]
	147.2	71	[30]
	81.0	71	[28]
	91.4	53	[11]
	73.0	57	[28]
Glulisine	92.0	83	[28]
	82.0	55	[29]
	18.9	180	[31]
Glargine	13.5		[32]
	20.0		[32]
NPH	22.8	360	[31]
	21.3	200	[30]

Note. Shown are reported values of C_{max} and t_{max} in studies about insulin analog products [11,26–32]. Glargine's t_{max} was deduced from the time–concentration plot in Ref. [31].




Fig. 7. Relations between HDX kinetic parameters and C_{max} (A) or t_{max} (B) values.

Discussion

Since insulin lispro was first sold in 1995 as an analog of recombinant human insulin, many insulin analog products have been marketed. Oligomeric stability of formulated analogs is important for controlling their onset and duration of action. In this study, we analyzed the oligomeric stability of formulated insulin analogs by HDX/MS, which is an analytical method to determine structural fluctuations of proteins, and we investigated relationships between the parameters of HDX kinetics and pharmacokinetics of the analogs.

We first measured the diameters of the formulated insulin analogs under the same conditions as the HDX reaction. The diameters of two rapid-acting analogs (lispro and glulisine), which have low oligomeric stability, were smaller than that of human insulin at low concentrations, although glargine, a long-acting analog, formed large aggregates with an increase in pH by neutralization (Fig. 4). These results are consistent with previous studies and provide evidence that rapid-acting analogs dissociate more easily than human insulin and glargine forms aggregates at physiological pH. Detemir, another long-acting analog, exhibited unique behavior. It did not form huge aggregates like glargine, but it had larger diameters with dilution; its mean diameters were 2- or 3-fold larger than those of human insulin. This would have resulted from the suggested complex of detemir hexamers mediated by their acyl chains [33,34].

Next, we determined the HDX reactivity of human insulin and insulin analogs of rapid-, long-, and intermediate-acting groups (Fig. 5). Lispro and glulisine incorporated more deuteriums than human insulin. On the other hand, glargine and two products of the intermediate-acting group (NPH and NPL) incorporated fewer deuteriums than human insulin. These results demonstrate that HDX reactivity of insulin analogs at neutral pH were associated with their oligomeric stability. Interestingly, detemir, in spite of its prolonged action, had exchange reactivity similar to that of human insulin. Considering the mechanism in which detemir hexamers associate, there could be little effect on the solvent accessibility of peptide moieties of detemir molecules even when their hexamers form a larger complex.

The PCA using kinetic parameters of the HDX reactions resulted in a distinction among the three groups (Fig. 6). Two analogs of the rapid-acting group, one long-acting preparation, and two intermediate-acting preparations were plotted at close positions. However, detemir was plotted far from the other analogs of long- and intermediate-acting groups and was closer to human insulin. This result was in agreement with the time-dependent incorporation of deuteriums (Fig. 4). We suggest that only four kinetic parameters (D_{∞} , D_f , D_i , and D_s) obtained by HDX/MS allow for discrimination of insulin analogs of different groups. In addition, PCA using the kinetic parameters could also be applicable to evaluate similarities in similar biological medicinal products of insulin analogs under development.

We analyzed the association between the HDX kinetic parameters and the actual pharmacokinetic parameters in humans. We compared previously reported values of C_{\max} and t_{\max} (Table 5) with our kinetic parameters (Table 4). This resulted in the correlations with D_{∞} and D_s shown in Fig. 7. These results suggest that D_{∞} and D_s could be useful as characteristic markers for prediction of C_{\max} and t_{\max} . In a previous study on HDX with human insulin and lispro reported by Chitta and coworkers [25], D_{∞} values were nearly equal to the total number ($D_f + D_i + D_s$) of amide deuteriums in the peptide backbone. However, in our study, the total number of D_f , D_i , and D_s was from 30% to 51% of D_{∞} , indicating that there could be some deuteriums left in side chains. Differences from the previous study could be caused by the difference in the temperature at which the HDX reaction was performed. In other words, continuous cooling through the entire procedure of HDX to moderate the exchange reaction in our study could account for the differences. Chitta and coworkers also reported a difference in D_i between human insulin and lispro [25], whereas in our study the only difference was observed in the D_s numbers. On ice, incubation could have switched some of the fast hydrogens to intermediate hydrogens and switched some of the intermediate hydrogens to slow hydrogens.

The concentration of insulin is a significant factor that affects the association and dissociation of insulin oligomer [24] and, thus, also affects the HDX reactivity [25]. When comparing the oligomeric

stability of insulin preparations by HDX/MS, one should be careful about sample concentration because the difference in HDX reactivity could attenuate if insulin concentration were too high to dissociate (or too low to form even dimer).

Finally, we demonstrated the utility and capability of the HDX/MS method for evaluating the oligomeric stability of insulin analog products. We also revealed relationships between some HDX kinetic parameters and pharmacokinetic parameters. We believe that our current method could be helpful in predicting the pharmacokinetics of insulin analogs.

Acknowledgment

This study was supported in part by a Grant-in-Aid from the Ministry of Health, Labour, and Welfare (Japan).

References

- [1] J. Brange, D.R. Owens, S. Kang, A. Volund, Monomeric insulins and their experimental and clinical applications, *Diabetes Care* 13 (1990) 923–954.
- [2] M.R. DeFelippis, R.E. Chance, B.H. Frank, Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics, *Crit. Rev. Ther. Drug Carrier Syst.* 18 (2001) 201–264.
- [3] J. Brange, A. Volund, Insulin analogs with improved pharmacokinetic profiles, *Adv. Drug Deliv. Rev.* 35 (1999) 307–335.
- [4] J.A. Mayfield, R.D. White, Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function, *Am. Fam. Physician* 70 (2004) 489–500.
- [5] S.N. Charugulla, T.S. Kamat, K. Peetambaran, V.M. Thorat, Insulin analogues: an update, *Res. J. Krishna Inst. Karad* 2 (2009) 6–12.
- [6] NIH Daily Med, HUMULIN (insulin human) injection, solution (Eli Lilly and Company). 2011. Available from: <<http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=43212>>.
- [7] C. Binder, A theoretical model for the absorption of soluble insulin, in: P. Brunetti (Ed.), *Artificial Systems for Insulin Delivery*, Raven, New York, 1983, pp. 53–57.
- [8] C.J. Dunn, G.L. Plosker, G.M. Keating, K. McKeage, L.J. Scott, Insulin glargine: an updated review of its use in the management of diabetes mellitus, *Drugs* 63 (2003) 1743–1778.
- [9] O. Wintersteiner, H.A. Abramson, The isoelectric point of insulin, *J. Biol. Chem.* 99 (1933) 741–753.
- [10] T. Blundell, G. Dodson, D. Hodgkin, D. Mercola, Insulin: the structure in the crystal and its reflection in chemistry and biology, *Adv. Protein Chem.* 26 (1972) 279–402.
- [11] Eli Lilly Canada, Humalog product monograph. 2011. Available from: <<http://www.lilly.ca/servlets/sfs;jsessionid=2606BA9C69DD8DC6B024A9D13FEB97?=/documentManager/sfdoc.file.supply&e=UTF-8&i=1233164768976&l=0&s=254REX2uNLETASc&fileID=1299285990234>>.
- [12] European Medicines Agency Committee for Medicinal Products for Human Use, Apidra: European Public Assessment Report—Scientific Discussion. 2011. Available from: <http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000557/human_med_000648.jsp&url=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125#>.
- [13] G.B. Bolli, D.R. Owens, Insulin glargine, *Lancet* 356 (2000) 443–445.
- [14] U. Dashora, V. Dashora, Insulin glargine, *Int. J. Diabetes Dev. Countries* 20 (2000) 140–144.
- [15] D.L. Bakaysa, J. Radziuk, H.A. Havel, M.L. Brader, S. Li, S.W. Dodd, J.M. Beals, A.H. Pekar, D.N. Brems, Physicochemical basis for the rapid time-action of Lys^{B28}Pro^{B29}-insulin: dissociation of a protein–ligand complex, *Protein Sci.* 5 (1996) 2521–2531.
- [16] A. Hvidt, K. Linderström-Lang, Exchange of hydrogen atoms in insulin with deuterium atoms in aqueous solutions, *Biochim. Biophys. Acta* 14 (1954) 574–575.
- [17] S.W. Englander, L. Mayne, Y. Bai, T.R. Sosnick, Hydrogen exchange: the modern legacy of Linderström-Lang, *Protein Sci.* 6 (1997) 1101–1109.
- [18] Y. Hamuro, S.J. Coales, M.R. Southern, J.F. Nemeth-Cawley, D.D. Stranz, P.R. Griffin, Rapid analysis of protein structure and dynamics by hydrogen/deuterium exchange mass spectrometry, *J. Biomol. Tech.* 14 (2003) 171–182.
- [19] X. Yan, J. Watson, P.S. Ho, M.L. Deinzer, Mass spectrometric approaches using electrospray ionization charge states and hydrogen–deuterium exchange for determining protein structures and their conformational changes, *Mol. Cell. Proteomics* 3 (2003) 10–23.
- [20] S.W. Englander, D.B. Calhoun, J.J. Englander, N.R. Kallenbach, R.K. Liem, E.L. Malin, C. Mandal, J.R. Rogero, Individual breathing reactions measured in hemoglobin by hydrogen exchange methods, *Biophys. J.* 32 (1980) 577–589.
- [21] Z.Q. Zhang, D.L. Smith, Determination of amide hydrogen exchange by mass spectrometry: a new tool for protein structure elucidation, *Protein Sci.* 2 (1993) 522–531.
- [22] J.R. Engen, D.L. Smith, Investigating protein structure and dynamics by hydrogen exchange MS, *Anal. Chem.* 73 (2001) 256A–265A.

- [23] H. Maity, W.K. Lim, J.N. Rumbley, S.W. Englander, Protein hydrogen exchange mechanism: local fluctuations, *Protein Sci.* 12 (2003) 153–160.
- [24] E.J. Nettleton, P. Tito, M. Sunde, M. Bouchard, C.M. Dobson, C.V. Robinson, Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry, *Biophys. J.* 79 (2000) 1053–1065.
- [25] R.K. Chitta, D.L. Rempel, M.A. Grayson, E.E. Remsen, M.L. Gross, Application of SIMSTEX to oligomerization of insulin analogs and mutants, *J. Am. Soc. Mass Spectrom.* 17 (2006) 1526–1534.
- [26] S.R. Mudaliar, F.A. Lindberg, M. Joyce, P. Beerdsen, P. Strange, A. Lin, R.R. Henry, Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin—absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects, *Diabetes Care* 22 (1999) 1501–1506.
- [27] A. Lindholm, J. McEwen, A.P. Riis, Improved postprandial glycemic control with insulin aspart: a randomized double-blind cross-over trial in type 1 diabetes, *Diabetes Care* 22 (1999) 801–805.
- [28] R.H. Becker, A.D. Frick, Clinical pharmacokinetics and pharmacodynamics of insulin glulisine, *Clin. Pharmacokinet.* 47 (2008) 7–20.
- [29] European Medicines Agency Committee for Medicinal Products for Human Use, Apidra: European Public Assessment Report—Product Information. 2011. Available from: <http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000557/WC500025250.pdf>.
- [30] T. Heise, C. Weyer, A. Serwas, S. Heinrichs, J. Osinga, P. Roach, J. Woodworth, U. Gudat, L. Heinemann, Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin, *Diabetes Care* 21 (1998) 800–803.
- [31] M. Lepore, S. Pampanelli, C. Fanelli, F. Porcellati, L. Bartocci, A.D. Vincenzo, C. Cordoni, E. Costa, P. Brunetti, G.B. Bolli, Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro, *Diabetes* 49 (2000) 2142–2148.
- [32] G.A. Brunner, G. Sendhofer, A. Wutte, M. Ellmerer, B. Søgaard, A. Siebenhofer, S. Hirschberger, G.J. Krejs, T.R. Pieber, Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans, *Exp. Clin. Endocrinol. Diabetes* 108 (2000) 100–105.
- [33] J.L. Whittingham, S. Havelund, I. Jonassen, Crystal structure of a prolonged-acting insulin with albumin-binding properties, *Biochemistry* 36 (1997) 2826–2831.
- [34] S. Havelund, A. Plum, U. Ribel, I. Jonassen, A. Vølund, J. Markussen, P. Kurtzhals, The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin, *Pharm. Res.* 21 (2004) 1498–1504.

再生医療製品の品質評価におけるグライコミクス

橋井 則貴, 中澤 志織, 川崎 ナナ*

Glycomics in Quality Control of Tissue-engineered Medical Products

Noritaka Hashii, Shiori Nakazawa, and Nana Kawasaki*

National Institute of Health Sciences; 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.

(Received December 2, 2011)

Glycosylation of cells is known to alter with several biological events such as cell differentiations and proliferations as well as some diseases. “Glycomics approaches”, comprehensive qualitative and quantitative glycan analyses of the cells, have become increasingly important as a means of discovering biomarkers that have the potential of being used as disease diagnostic markers and molecular markers for cell characterizations. In this paper, we introduce a method of quantitative glycan profiling by liquid chromatography/mass spectrometry with a combination of an isotope tagging method. In addition, we demonstrate the potential of glycan profiling as a tool for the identification of differentiated human bone marrow mesenchymal stem cell (hMSC) and non-differentiated hMSC.

Key words—glycan profiling; quantitative glycan analysis; isotope tagging method

1. はじめに

細胞に存在するタンパク質の多くは糖タンパク質であり、糖鎖部分の構造や分布は、がんや自己免疫疾患などある種の疾患、細胞分化等の生命現象、あるいは細胞環境の変化などに伴い変化することが知られている。¹⁻⁶⁾ がん化や分化の過程で変動する糖鎖を見い出すことは、疾患の診断マーカーや細胞の分子マーカーの開発等につながる可能性がある。糖鎖は遺伝子の直接的な産物ではなく、様々な酵素反応を経て合成される二次的産物であるため、遺伝子解析から構造や分布の変化を推定することは容易ではない。糖鎖の変化を明らかにするためには、表現型である細胞中の糖鎖を直接解析することが肝要であり、細胞糖鎖（グライコーム）の質的・量的な変化を網羅的に解析するグライコミクスに高い関心が集まっている。

グライコーム解析の手法として、レクチンを用いる方法、キャピラリー電気泳動法、質量分析法（MS）、及び蛍光標識 HPLC を用いる方法などがあ

る。⁷⁾ これまでにわれわれは、液体クロマトグラフィー/質量分析（LC/MS）を用いた糖鎖プロファイリング法を開発し、疾患モデルマウスのグライコーム解析などに応用してきた。^{8,9)} 本分析法は、遊離糖鎖の還元末端を誘導体化し、グラファイトカーボンカラムを用いた LC により糖鎖を微細構造の違いで分離しながら、オンラインによる分子の質量測定、並びに多段階質量分析（MSⁿ）を行い、糖鎖の分布と各糖鎖の構造を推定する方法である。^{9,10)} 本稿では、本分析法を再生医療での応用が期待されている同種体性幹細胞のグライコーム解析に応用した例を紹介する。

2. ヒト間葉系幹細胞の糖鎖プロファイリング

ヒト幹細胞を用いる臨床研究は、臓器機能再生等を通じて国民の健康の維持並びに疾病の予防、診断及び治療に重要な役割を果たすものと考えられており、2006年7月の「ヒト幹細胞を用いた臨床研究に関する指針」の施行以後、2011年3月現在、28件の臨床研究が承認されている。これらを再生医療品開発につなげるためには、品質管理の一環として、適切な生化学的指標、免疫学的指標、特徴的産生物質など適切な遺伝型あるいは表現型の指標を選択して、目的とする細胞・組織であることを確認するための手法を確立する必要がある。細胞の糖鎖は

国立医薬品食品衛生研究所（〒158-8501 東京都世田谷区上用賀 1-18-1）

*e-mail: nana@nihs.go.jp

本総説は、日本薬学会第 131 年会シンポジウム S16 で発表したものを中心に記述したものである。

がん化や分化などに伴い変化することから、目的とする細胞・組織の評価指標の1つとして利用できる可能性が高い。

Figure 1は、再生医療への応用が期待されているヒト骨髄由来間葉系幹細胞 (hMSC) の糖鎖プロファイルである。hMSCは、多能性を有する体性幹細胞であり、骨、軟骨、脂肪及び神経様の細胞に分化することが知られている。^{11,12} iPS細胞やhMSCなどが再生医療製品として応用可能になったとき、特性解析や品質管理等に利用できる細胞数には制限があると予想されることから、微量分析が可能な試験法の設定が求められる。LC/MSにより、わずか 2×10^5 個のhMSCから糖鎖分布を示すトータルイオンカレントクロマトグラム (TICC) を得ることができた。実線は、ポジティブイオンモードにより得られたTICCで、主に中性糖鎖 (高マンノース

型、パウチマンノース型糖鎖、混成型、及びアシアロ複合型糖鎖) の分布を示している。破線は、ネガティブイオンモードで得られたTICCで、酸性糖鎖 (シアロ糖鎖) の分布を示している。Figure 1中の糖鎖構造は、各ピークに含まれる主な糖鎖の推定構造であり、MSによるフルスキャン (m/z 700–2000) で得られた分子関連イオンの質量と MS^n により取得されたプロダクトイオンの質量から推定している。hMSCに結合している糖鎖の種類は、高マンノース型糖鎖、パウチマンノース型糖鎖、混成型糖鎖、及び複合型糖鎖と幅広く、複合型糖鎖にはNアセチルノイラミン酸 (NeuNAc) とフコース (Fuc) の結合数に不均一性がみられる。LC/MSで得られるピーク間の強度比は、糖鎖の結合比を正確には反映していないが、ピークのパターンから、中性糖鎖では高マンノース型糖鎖 M8 及び M9 が多いこと




Fig. 1. Total Ion Current Chromatogram (TICC) Obtained by LC/MS of Reduced *N*-linked Glycans Prepared from hMSC

The solid line and the dashed line denote chromatograms obtained by LC/MS in the positive ion mode and the negative ion mode, respectively. LC, Paradigm MS4 HPLC system (Michrom BioResources); MS, LTQ-FT (Thermo Fisher Scientific); column, graphitized carbon column (0.075 × 150 mm; particle size, 5 μm); mobile phase, 5 mM ammonium bicarbonate containing 2% acetonitrile (A buffer) and 5 mM ammonium bicarbonate containing 80% acetonitrile (B buffer); flow rate, 300 nL/min; gradient condition, 2–45% B buffer (60 min); electrospray voltage, 2.5 kV in the positive and negative ion modes. ▲, fucose (Fuc); ●, mannose (Man); ○, galactose (Gal); ■, *N*-acetylglucosamine (GlcNAc); ◆, *N*-acetylneuraminic acid (NeuNAc).




Fig. 2. Glycan Distribution in hMSC

The relative peak intensity of each glycan is expressed as a percentage of the total peak intensity of the glycans. Error bars represent the standard deviations. (A), Distribution of neutral glycans (positive ion mode); (B), distribution of sialylated glycans (negative ion mode). dHex, deoxyhexose; Hex, hexose; HexNAc, N-acetylhexosamine; NeuNAc, N-acetylneuraminic acid.

[Fig. 2(A)], また、酸性糖鎖では、生合成後期にあらわれる分岐鎖の多い糖鎖が少ないことが示唆された [Fig. 2(B)].

3. 細胞発現糖鎖の比較定量解析

Figure 3(A)は、未処理 hMSC の光学顕微鏡像である。hMSC を骨細胞に分化誘導し、顕微鏡により形態学的な変化を観察すると、14日目からカルシウムの沈着が観察され、誘導後21日目には、細胞の約70%にカルシウムの沈着がみられる [Fig. 3(B)]. 脂肪細胞への分化では、誘導開始7日目から脂肪滴が観察され始め、21日目には多くの細胞で脂肪滴の蓄積が観察される [Fig. 3(C)]. Figure 3(D)は MSC を神経様細胞に分化誘導後2日目の細胞であり、細胞質部分の繊維状から球状への変化、及び突起の伸長が観察され、神経細胞の形態学的な特徴を有していることがわかる。これらの分化を評価する方法として、免疫組織化学染色法やフローサイトメトリー法などにより、分化細胞に特異的に発現するタンパク質の発現の有無を確認する方法が知られている。しかし、神経様分化細胞のマーカーとして使用されているタンパク質の多くは未分化の hMSC にも発現されており、特異性に課題があることが指摘されている。¹³⁾ hMSC とその神経様分化細胞で結合量に差異が認められる糖鎖を見出すことができれば、より特異性の高いマーカーとし

て利用できる可能性がある。そのためには、神経様分化前後の細胞の糖鎖分布を比較できる定量的解析手法が必要である。

LC/MS では、ピーク強度の再現性に依然として問題があり、複数のサンプル間で量的な比較を行うためには、同位体標識法や、統計的解析手法を用いる必要がある。筆者らは、重水素 (D) 置換 2-アミノピリジン (2AP) により調製した 4D 置換ピリジルアミノ化 (PA) 糖鎖を用いた比較定量法を開発している (Fig. 4).¹⁴⁾ この方法は、比較する試料 A 並びに B から酵素的あるいは化学的に糖鎖を切り出し、それぞれ D 未置換 PA 糖鎖 (d_0 -PA 糖鎖) 並びに d_4 -PA 糖鎖とし、混合して LC/MS で分析する方法である [Fig. 4(A)]. d_0 -PA 糖鎖と d_4 -PA 糖鎖は、糖鎖部分の構造の差異に基づいて分離されるが [Fig. 4(B)], マススペクトル上、質量 4 u 差のイオンとして分離される [Fig. 4(C)]. 糖鎖量の違いはピーク強度の違いとなってあらわれるので、ピーク強度比を求めることにより、糖鎖結合比を得ることができる。

われわれの報告に続き、D 標識された 1-フェニル-3-メチル-5-ピラゾロン (PMP) や ^{13}C で標識したアラニン、2-アミノ安息香酸を用いて還元末端を標識する方法が相次いで報告された (Table 1). また ^{13}C で標識されたヨウ化メチルで糖鎖を全メチル




Fig. 3. Cell Images of hMSC and Its Differentiated Cells Taken by a Light Microscope (A), hMSC; (B), osteogenic differentiation; (C), adipogenic differentiation; (D), neural differentiation.




Fig. 4. Quantitative Glycan Analysis by a Combination of Isotope Tagging Method
 (A), Strategy for quantitative glycan analysis using d_0 -2AP and d_6 -2AP as labeling reagents; (B), chromatogram obtained by the LC/MS of a mixture of d_0 -PA and d_4 -PA-glycans; (C), mass spectra obtained from a mixture of d_0 -PA and d_4 -PA-glycans.

化する方法も報告されている。¹⁵⁻¹⁹⁾ これらの方法の多くは、酸性溶液中で加熱して糖鎖を誘導体化する方法であり、シアル酸が解離する可能性があることから、シアロ糖鎖が多い hMSC には適切でない。そこでわれわれは、中性水溶液中で標識が可能なフェニルヒドラジン (PHN) を用いた、新たな糖鎖同位体標識法を開発した [Fig. 5(A)].²¹⁾ この方法は、糖鎖試料溶液に、六炭素が ¹³C で置換された PHN (¹³C₆-PHN) 塩酸塩又は未置換 PHN (¹²C₆-PHN) 塩酸塩、並びに還元剤 2-ピコリボランを加えて遮光下 55°C で 1 時間程度反応させる方法である [Fig. 5(B)].^{22,23)} 反応終了後、クロロホルム抽出により、過剰な PHN 及び 2-ピコリボランを除くことができるので、標識後の後処理も簡単である。Figure 6 は、ジシアロ 2 本鎖糖鎖の ¹²C₆-PHN 標識体及び ¹³C₆-PHN 標識体の等量混合物のマススペクトルであり、*m/z* 1231.5 及び *m/z* 1234.5 に、それぞれ ¹²C₆-PHN 標識体及び ¹³C₆-PHN 標識体の 2 価イオンが観測されている。両者の質量差は 6 u であり、天然に存在する同位体の影響は少ない。

この PHN 標識法と LC/MS を用いて、未分化 hMSC と神経様に分化した hMSC の糖鎖結合量を比較定量した結果が Fig. 7 である。上向きのカラムは未分化細胞よりも神経様分化細胞で多かった糖鎖で、未分化細胞の糖鎖を 1.0 としたときの相対比、また、下向きのカラムは神経様細胞よりも未分化細胞で多かった糖鎖で、神経様分化細胞の糖鎖を 1.0 としたときの相対比を表している。hMSC を神経様細胞に分化誘導すると、Fuc 結合複合型糖鎖の高分岐化が進む一方で、3 及び 4 個の NeuNAc が結合し、かつ Fuc が結合していない複合型 3 本鎖糖鎖の割合は減少する傾向にあることがわかる。この結果は、hMSC の神経様分化において、2 日間で糖鎖のプロファイルが変わること、換言すれば、糖鎖プロファイルを比べることによって、未分化細胞と神経様分化細胞を識別できる可能性を示唆していると思われる。

4. おわりに

本稿では、再生医療での応用が期待されている hMSC を用いて、LC/MS によるグライコーム解析法が、細胞分化の評価に応用できる可能性があることを示した。これまでグラコミクスは、主にがんなどの診断マーカー探索研究の 1 つとして展開されて

Table 1. Isotope Tagging Method Using Various Reagents

Tagging reagent	Isotope	Mass difference	Solvent	Reaction temperature (°C)	Time (h)	Reducing agent	Reaction temperature (°C)	Time (h)	Sample cleanup	Reported year	Reference
2-Aminopyridine (PA)	² H (D)	4	30% AcOH in DMSO	90	1	Borane-dimethylamine complex	80	1	Graphitized carbon cartridge (d)	2005	14
Aniline	¹³ C	6	30% AcOH in DMSO	65	2-4	NaCNBH ₃	—(b)	—	Paper chromatography cartridge (e) Paper disk (f)	2008, 2009	15, 16
2-Aminobenzoic acid (2-AA)	¹³ C	6	2.7% AcONa, 1.3% boric acid, 33% THF	80	1	NaCNBH ₃	—(b)	—	Normal phase cartridge, graphitized carbon cartridge (g)	2010	17
1-Phenyl-3-methyl-5-pyrazolone (PMP)	² H (D)	10	10.5% NH ₃ in CH ₃ OH	70	1.5	—(c)	—(c)	—	Extraction with dichloromethane	2011	20
Permethylation	¹³ C	—(a)	DMSO	<25	>4	—(c)	—(c)	—	Extraction with chloroform	2007	18, 19

(a), Mass difference between ¹³C-labeled sample and ¹²C-labeled sample changes depending on glycan; (b), amination and reduction were performed by a one-step process; (c), reduction is not performed; (d), Envi-Carb (Supelco); (e), GlycoClean S (Prozyme); (f), 3-MM paper filter (Whatman); (g), normal phase DPA-6S PhyTips and Carbo-pack tips (PhyNeous).




Fig. 5. Tagging of Glycan with Phenylhydrazine (PHN)

(A), Reaction mechanism of glycan tagging with PHN; (B), preparation of PHN labeled glycan.




Fig. 6. Mass Spectrum of a Mixture of ¹²C₆-PHN and ¹³C₆-PHN Labeled Disialylated Core-fucosylated Complex Type Biantennary




Fig. 7. Quantitative Glycan Analysis between hMSC (untreated cell) and Its Neural-lineage Cell (treated cell). Each value is the average of a triplicate. Error bars represent the standard deviations.

きたが、それらの研究を通して確立された様々な技術が、今後、再生医療製品の品質管理手法の1つとしても発展していくことが期待される。

謝辞 本研究は、厚生労働科学研究費補助金並びに科学研究費補助金若手 (B) の研究成果の一部である。

REFERENCES

- 1) Feizi T., Gooi H. C., Childs R. A., Picard J. K., Uemura K., Loomes L. M., Thorpe S. J., Hounsell E. F., *Biochem. Soc. Trans.*, **12**, 591–596 (1984).
- 2) Kannagi R., Izawa M., Koike T., Miyazaki K., Kimura N., *Cancer Sci.*, **95**, 377–384 (2004).
- 3) Lau K. S., Partridge E. A., Grigorian A., Silvescu C. I., Reinhold V. N., Demetriou M., Dennis J. W., *Cell*, **129**, 123–134 (2007).
- 4) Heiskanen A., Hirvonen T., Salo H., Impola U., Olonen A., Laitinen A., Tiitinen S., Natunen S., Aitio O., Miller-Podraza H., Wuhrer M., Deelder A. M., Natunen J., Laine J., Lehenkari P., Saarinen J., Satomaa T., Valmu L., *Glycoconj. J.*, **26**, 367–384 (2009).
- 5) Miyoshi E., Shinzaki S., Moriwaki K., Matsumoto H., *Methods Enzymol.*, **478**, 153–164 (2010).
- 6) Hossler P., Khattak S. F., Li Z. J., *Glycobiology*, **19**, 936–949 (2009).
- 7) Hirabayashi J., Kuno A., Tateno H., *Electrophoresis*, **32**, 1118–1128 (2011).
- 8) Hashii N., Kawasaki N., Itoh S., Nakajima Y., Kawanishi T., Yamaguchi T., *Immunology*, **126**, 336–345 (2009).
- 9) Hashii N., Kawasaki N., Itoh S., Hyuga M., Kawanishi T., Hayakawa T., *Proteomics*, **5**, 4665–4672 (2005).
- 10) Itoh S., Kawasaki N., Hashii N., Harazono A., Matsuishi, Hayakawa T., Kawanishi T., *J. Chromatogr. A*, **1103**, 296–306 (2006).
- 11) Prockop D. J., *Science*, **276**, 71–74 (1997).

- 12) Sanchez-Ramos J., Song S., Cardozo-Pelaez F., Hazzi C., Stedeford T., Willing A., Freeman T. B., Saporta S., Janssen W., Patel N., Cooper D. R., Sanberg P. R., *Exp. Neurol.*, **164**, 247–256 (2000).
- 13) Tondreau T., Lagneaux L., Dejenefte M., Massy M., Mortier C., Delforge A., Bron D., *Differentiation*, **72**, 319–326 (2004).
- 14) Yuan J., Hashii N., Kawasaki N., Itoh S., Kawanishi T., Hayakawa T., *J. Chromatogr. A*, **1067**, 145–152 (2005).
- 15) Xia B., Feasley C. L., Sachdev G. P., Smith D. F., Cummings R. D., *Anal. Biochem.*, **387**, 162–170 (2009).
- 16) Lawrence R., Olson S. K., Steele R. E., Wang L., Warrior R., Cummings R. D., Esko J. D., *J. Biol. Chem.*, **283**, 33674–33684 (2008).
- 17) Prien J. M., Prater B. D., Qin Q., Cockrill S. L., *Anal. Chem.*, **82**, 1498–1508 (2010).
- 18) Alvarez-Manilla G., Warren N. L., Abney T., Atwood J. 3rd, Azadi P., York W. S., Pierce M., Orlando R., *Glycobiology*, **17**, 677–687 (2007).
- 19) Kang P., Mechref Y., Kyselova Z., Goetz J. A., Novotny M. V., *Anal. Chem.*, **79**, 6064–6073 (2007).
- 20) Zhang P., Zhang Y., Xue X., Wang C., Wang Z., Huang L., *Anal. Biochem.*, **418**, 1–9 (2011).
- 21) Lattova E., Perreault H., *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.*, **793**, 167–179 (2003).
- 22) Sato S., Sakamoto T., Miyazawa E., Kikukawa Y., *Tetrahedron*, **60**, 7899–7906 (2004).
- 23) Ruhaak L. R., Steenvoorden E., Koeleman C. A., Deelder A. M., Wuhrer M., *Proteomics*, **10**, 2330–2336 (2010).